The Centre of New Technologies invites to a webinar by
Jakub Godlewski, PhD
Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego, Warszawa
Title: NON-CODING RNA: FROM DARK MATTER TO THE REAL DEAL
Date: 5 th November 2021, Friday
Time: 1:00 pm (Central European Time)
Host: Jeff Palatini, PhD
Zoom link: https://us02web.zoom.us/j/82426581314
Seminars can also be watched in the Auditorium (room 0142).
To subscribe to receive announcements about CeNT UW seminars or to unsubscribe please click here
CeNT-UW-Webinars-instruction-for-attendees
Abstract:
The presentation will cover several aspects of the non-coding RNA – a vast amount of RNA that does not encode for proteins, yet is produced at high cost by all our cells, often in cell-, tissue-, and
physiopathological condition-specific manner, suggestive of an intricate regulatory network. Scientists in the bio-medical field tended to overlook the importance of non-coding RNA, often missing their critical chance in discovering therapeutic targets and developing therapeutic agents. This talk will present the evolution of our understanding of the role and importance of non-coding RNA from “dark matter” or even “junk” to bonafide biomarkers and therapeutic targets in various pathologies. The talk will give participants overlook of the complexity of the universe of non-coding RNAs, their classification, role, and impact, providing a new layer in our understanding of physiopathology. Using deadly brain tumor – glioblastoma as a model (the author will disclose basic details on disease’s key aspects), and several noteworthy examples generated by over 15 years of research by the author’s group, the participants will be presented various aspects of the pathobiology of several key players in non-coding RNA world: microRNAs, long non-coding RNAs, and circular RNAs. These aspects will include disease-related (causal vs. causative) changes in their prevalence, their molecular and phenotypic footprint (with only superficial scrutiny of their mechanistic roles), and finally, their usefulness as either therapeutic targets or therapeutic agents in the development of experimental pre-clinical therapeutic avenues against glioblastoma.
